Microbiome Development 2018
17th - 18th September 2018, Basel, Switzerland
It will bring together leaders and industry experts in microbiome drug discovery & development to help accelerate the precise translation of microbiome R&D from disease causation into safe, effective and commercially scalable therapeutics.
Using insight gained from the most successful microbiome organizations across the globe, the only end to end drug development meeting is back to help accelerate emerging and well established companies discover, develop and deliver a new generation of microbiome-based therapeutics.
The Microbiome industry is growing rapidly, with increased investment and a number of therapeutics in clinical development. As of yet, no drugs have been approved. Microbiome research therefore represents an exciting new area of drug discovery. The profound impact that microbial communities have on human health is providing new therapeutic and diagnostic modalities to effectively treat disease. As a result of this excitement, the human microbiome has become a gold mine of opportunity for emerging biotech, established pharmaceutical companies, investors and researchers.
Learn, share and collaborate with organizations using novel drug modalities including Seres Therapeutics, Vedanta Biosciences, Rebiotix, Enterome, 4D Pharma, Gusto Global, AstraZeneca, Janssen R&D, GSK, Merck, Pfizer and many more at the Microbiome Development 2018
The BioTech Pharma Summit: Microbiome Development 2018 will give you the opportunity to get unprecedented access to the latest preclinical, clinical and commercial case studies from the brightest minds in biopharma and academia to turn microbiome discoveries of today into patient therapies of the future.